Rubinger D, Weiss O, Zarfati D, Popovtzer M M, Raz I
Nephrology and Hypertension Services and Department of Medicine, Hadassah University Hospital, POB 12000, Jerusalem 91120, Israel.
J Endocrinol. 1998 Oct;159(1):133-40. doi: 10.1677/joe.0.1590133.
The present study was undertaken to assess the chronic effects of low dose octreotide (Oc) administration in rats with experimental diabetes mellitus (DM). Metabolic and clearance studies were performed in control normal rats, in rats with streptozotocin-induced DM of 1 week duration and in similar DM rats treated with Oc, 10-20 microg/day. Gene expression of IGF-I, IGF-I receptor (IGF-I R) and IGF-binding protein-1 (IGFBP-1) was examined in renal tissue from normal DM animals and DM animals treated with Oc 10, 20 and 100 microg/day. Seven days of Oc administration, 10 microg/day, in rats with experimental DM, was associated with enhanced hyperglycemia, increased glomerular filtration rate and urinary sodium excretion as compared with untreated DM animals. After a higher Oc dose, 20 microg/day, however, there were no significant changes in renal function and in glycemic control. Significant increases in kidney weight and kidney weight/body weight ratio were seen in DM rats as compared with control intact animals. These changes were not affected by Oc therapy in various doses. Induction of DM was associated with a marked increase in renal IGFBP-1 mRNA expression. There were no significant changes in the expression of IGF-I or IGF-I R mRNA. Oc therapy in a low or high dose did not affect gene expression of IGF-I, IGF-I R or IGFBP-1. Thus, the response to chronic low dose Oc administration of DM rats may vary from enhanced hyperglycemia and hyperfiltration to a lack of change in renal function or in glycemic control. Low dose Oc therapy was not associated with significant variations in renal mass or in the gene expression of IGF-I axis components. These findings are at variance with previously published studies which show a suppressive effect of Oc on renal function and growth in experimental diabetes. This apparent discrepancy may be related to the duration of treatment or to a biphasic physiological effect of Oc when used in different doses.
本研究旨在评估低剂量奥曲肽(Oc)给药对实验性糖尿病(DM)大鼠的慢性影响。在对照正常大鼠、链脲佐菌素诱导的病程为1周的DM大鼠以及用10 - 20微克/天的Oc治疗的类似DM大鼠中进行了代谢和清除研究。检测了正常DM动物以及分别用10、20和100微克/天的Oc治疗的DM动物肾组织中IGF-I、IGF-I受体(IGF-I R)和IGF结合蛋白-1(IGFBP-1)的基因表达。与未治疗的DM动物相比,给实验性DM大鼠每天注射10微克的Oc,持续7天,会导致高血糖加剧、肾小球滤过率增加和尿钠排泄增加。然而,在较高的Oc剂量(20微克/天)下,肾功能和血糖控制没有显著变化。与对照完整动物相比,DM大鼠的肾脏重量和肾脏重量/体重比显著增加。这些变化不受不同剂量Oc治疗的影响。DM的诱导与肾IGFBP-1 mRNA表达的显著增加有关。IGF-I或IGF-I R mRNA的表达没有显著变化。低剂量或高剂量的Oc治疗均不影响IGF-I、IGF-I R或IGFBP-1的基因表达。因此,DM大鼠对慢性低剂量Oc给药的反应可能从高血糖和超滤增强到肾功能或血糖控制无变化不等。低剂量Oc治疗与肾脏质量或IGF-I轴成分的基因表达的显著变化无关。这些发现与先前发表的研究结果不同,先前的研究表明Oc对实验性糖尿病的肾功能和生长有抑制作用。这种明显的差异可能与治疗持续时间或Oc不同剂量使用时的双相生理效应有关。